Research programme: antisense therapies - Ionis Pharmaceuticals

Drug Profile

Research programme: antisense therapies - Ionis Pharmaceuticals

Alternative Names: single-stranded RNAi - Ionis; ssRNAi - Ionis

Latest Information Update: 21 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Ionis Pharmaceuticals; Suzhou Ribo Life Science
  • Class Antisense oligonucleotides; Small interfering RNA
  • Mechanism of Action Protein synthesis inhibitors; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Metabolic disorders

Most Recent Events

  • 21 Apr 2017 Early research in Cancer in China (Parenteral)
  • 21 Apr 2017 Early research in Cancer in USA (Parenteral)
  • 18 Apr 2017 Suzhou Ribo Life Science enters into a license agreement with Ionis Pharmaceuticals for the right to commercialise two Ionis generation 2+ antisense drugs in Metabolic disorders and Cancer and an option to license a third pre-specified generation 2+ antisense drug in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top